TPN-101 is an oral small molecule tau metabolism modulator being developed for the treatment of Progressive Supranuclear Palsy (PSP). This Phase 2a study represents a critical milestone in the development of disease-modifying therapies for PSP, addressing the urgent unmet need for treatments that can slow or halt disease progression in this devastating neurodegenerative disorder[1].
| Field | Value |
|---|---|
| NCT ID | NCT04993768 |
| Status | Phase 2a (Completed) |
| Phase | Phase 2a |
| Sponsor | Translational Research Industries (TRI) |
| Study Design | Open-label, preliminary safety and tolerability |
| Intervention | TPN-101 oral administration |
| Enrollment | Approximately 40 participants |
| Condition | Progressive Supranuclear Palsy |
TPN-101 targets the core pathological mechanism in PSP: the abnormal metabolism and aggregation of tau protein. PSP is classified as a primary 4R-tauopathy[2].
The therapeutic approach reflects the growing understanding of tau propagation as a prion-like process[3]:
The tau hypothesis in PSP is strongly supported by multiple lines of evidence[4]:
| Approach | Examples | Advantages |
|---|---|---|
| Small Molecules | TPN-101, LMTM | Oral bioavailability |
| Active Immunization | AADvac1 | Long-lasting immunity |
| Passive Immunization | ABBV-8E12, E2814 | High specificity |
PSP manifests with multiple core symptoms[6]:
| Subtype | Prevalence | Key Features |
|---|---|---|
| Richardson's syndrome (PSP-RS) | ~50% | Classic presentation |
| PSP-parkinsonism (PSP-P) | ~25% | Better levodopa response |
| PSP-corticobasal syndrome (PSP-CBS) | ~10% | Cortical sensory loss |
| Pure akinesia with gait freezing (PAGF) | ~5% | Predominant gait freezing |
The hallmark lesion is neurofibrillary tangles composed of hyperphosphorylated 4R-tau. Key regions affected include[7]:
Current management is primarily supportive:
PSP clinical trials face unique challenges[8]:
The FDA has granted orphan drug designation to several PSP therapies, providing:
The tau protein is encoded by the MAPT gene on chromosome 17q21 and plays critical roles in neuronal physiology:
Isoforms: Alternative splicing produces six tau isoforms in the adult human brain:
Functions:
Post-Translational Modifications:
PSP is characterized by 4R-tau filament accumulation:
Neurofibrillary Tangles (NFTs):
Cellular Distribution:
Spreading Mechanism:
Irwin DJ, et al. Tau physiology and pathobiology in tauopathies. Annals of Neurology. 2013. ↩︎
Sweeney P, et al. Modeling Alzheimer's disease, tauopathy, and the prion-like spread of tau pathology. Methods in Molecular Biology. 2017. ↩︎
Boxer AL, et al. Tau-targeted therapies for Alzheimer disease and tauopathies. Nature Reviews Neurology. 2020. ↩︎
Vignoud G, et al. Tau imaging in progressive supranuclear palsy. Journal of Neurology. 2021. ↩︎
Stamelou M, et al. Progressive supranuclear palsy: Distinctive features and neuroimaging findings. Journal of Neurology. 2019. ↩︎
Lees AJ, et al. Neurobiology and pathophysiology of progressive supranuclear palsy. Movement Disorders. 2017. ↩︎
Litvan I, et al. Planning and designing clinical trials for progressive supranuclear palsy. Journal of Molecular Neuroscience. 2011. ↩︎